Echinococcosis / Brucellosis
A global leader and standard-setter in the surgical treatment of echinococcosis, this center boasts the world's largest single-center volume and most advanced technology for autologous liver transplantation in end-stage alveolar echinococcosis ("echinococcosis"). It is also a WHO Collaborating Centre for the Prevention and Management of Echinococcosis. The department's Digestive and Vascular Surgery Center is a National Key Clinical Specialty for Endemic Echinococcosis, ranking third in Northwest China for ten consecutive years in national hospital specialty rankings. Its autologous liver transplantation technique has been invited to participate in the development of international guidelines, making China a significant leader in the global prevention, diagnosis, and treatment of echinococcosis.
Technological breakthroughs: the "Xinjiang model" of autologous liver transplantation for end-stage alveolar echinococcosis, and the world's first breakthrough in nanosecond pulse ablation minimally invasive treatment.
- Ex vivo liver resection combined with autologous liver transplantation (ELRA). Professor Wen Hao pioneered autologous liver transplantation for the treatment of alveolar echinococcosis in 2010, overcoming the global medical challenge of radically curing end-stage "parasitic cancer." His team pioneered the "portal-caval shunt" technique to establish temporary blood flow pathways during ex vivo liver repair and improved the "autologous umbilical vein transplantation" technique to reconstruct damaged blood vessels using the patient's own umbilical vein. To date, over 220 cases have been completed, making it the single-center with the largest number of surgeries and the most mature technology globally, achieving a clinical cure rate of 90.1%, zero intraoperative deaths, and a 5-year survival rate of approximately 80%.
- Nanosecond pulse ablation (nanosecond knife) minimally invasive treatment. After ten years of independent research and development, Turgan Ali Aji's team completed the world's first nanosecond pulse ablation surgery for echinococcosis in June 2026. Under ultrasound guidance, the lesion was precisely removed using a 30,000-volt electric field and 1200 nanosecond pulses per 10 minutes. Local anesthesia was used, leaving only two needle marks on the skin, and the intrahepatic bile ducts, blood vessels, and nerves remained intact. This technology fills an international gap in minimally invasive and precise treatment of echinococcosis.
- Innovative radical surgical technique for cystic echinococcosis. Professor Wen Hao's innovative radical surgical technique has increased the cure rate of cystic echinococcosis from 5.23% to 88.9%, significantly reducing postoperative complications and recurrence rates.
- Technology Export and Promotion. Autologous liver transplantation technology has been exported to Beijing, Qinghai, Tibet, and other regions, and has also been used to assist Kazakhstan in performing its first autologous liver transplant. In 2024, the technology was invited to Germany to participate in the development of global guidelines for autologous liver transplantation.

